1. CEBM. Oxford Centre for Evidence-Based Medicine: Levels of Evidence 2009. [cited 20 January 2021]. Available from: https://www.cebm.ox.ac.uk/resources/Levels-of-evidence/oxford-centre-for-evidence-based-medicine-levels-of-evidence-march-2009
2. IgE-Mediated Multimorbidities in Allergic Asthma and the Potential for Omalizumab Therapy
3. Omalizumab beyond asthma
4. NICE. Omalizumab for treating severe persistent allergic asthma, 2013. [cited 2 January 2021]. Available from: www.nice.org.uk/guidance/ta278
5. NICE. Omalizumab for previously treated chronic spontaneous urticaria, 2015. [cited 2 January 2021]. Available from: www.nice.org.uk/guidance/ta339